Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597815 | 0.91 | TDP1 (0.57) | TDP1MMP9MMP13CTSLL3MBTL1 | |
| SCHEMBL5123529 | 0.91 | MMP13 (0.51) | TDP1MMP9MMP13CTSLITGB3 | |
| SCHEMBL4598594 | 0.91 | TDP1 (0.49) | TDP1MMP9MMP13CTSLITGB3 | |
| SCHEMBL4597834 | 0.91 | MMP13 (0.51) | TDP1MMP9MMP13CTSLITGB3 | |
| SCHEMBL4598174 | 0.90 | TDP1 (0.48) | TDP1MMP9MMP13CTSLITGB3 | |
| SCHEMBL4597080 | 0.86 | MMP13 (0.49) | TDP1MMP9MMP13ITGB3MEN1 | |
| SCHEMBL14045372 | 0.86 | MMP13 (0.49) | TDP1MMP9MMP13ITGB3MEN1 | |
| SCHEMBL4608941 | 0.85 | NPSR1 (0.53) | TDP1MMP9MMP13CTSLITGB3 | |
| SCHEMBL14045371 | 0.85 | NPSR1 (0.53) | TDP1MMP9MMP13CTSLITGB3 | |
| SCHEMBL14045407 | 0.83 | TDP1 (0.48) | TDP1MMP9MMP13CTSLITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | BEXEL PHARMACEUTICALS. INC. | 2008-08-21 | — | — | US | claimed |
| EP-1906731-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2007005603-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | claimed |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
| US-7456292-B2 | Hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456292-B2 | Hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | BEXEL PHARMACEUTICALS. INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | BEXEL PHARMACEUTICALS. INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1906731-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007005603-A2 | NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | TDP1 4051/4885MMP9 1292/4885MMP13 534/4885 |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | TDP1 3873/4885MMP9 1385/4885MMP13 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.